Browse Prescribing Notes by Therapeutic Subcategory

For menopausal disorders and female hormone replacement therapy (HRT) see Menopause & HRT section.

For erectile dysfunction see Erectile dysfunction section.
For osteoporosis see Bone disorders section.
For prostatic hyperplasia see Benign prostatic hyperplasia/urinary retention section.
For prostatic carcinoma see Prostate cancer section.
Testosterone is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, including: primary hypogonadism (eg, testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, trauma, or damage from alcohol or heavy metals) or hypogonadotropic hypogonadism (eg, idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or pituitary-hypothalamic injury). In healthy adult males, testosterone 4–7mg/day is produced in a circadian pattern in which the maximum levels are seen in the early AM and minimum levels are seen in the evening. The ideal replacement therapy would mimic the normal body rhythm and levels. Testosterone is available in a variety of delivery systems, including oral (modified and unmodified testosterone formulations), injections (eg, cypionate and enanthate salts), transdermal (eg, gels or patches), and buccal tablets. Patients receiving testosterone replacement should have their testosterone levels monitored to ensure the levels are within the normal range (298 to 1043nanograms/Liter) seen in healthy men.